腎細胞癌臨床成績の検討

Abstract

腎細胞癌95例について, 男女比は3:1, 平均年齢は男女共に61歳であった.主訴は血尿が最も多く44名, CT, USの普及による偶然発見者は18例あった.5年, 10年の生存は49名, 35名で, stage別の5年生存は1:35/42名, 2:4/8名, 3:4/21名, 4:1/24名となった.生存率は, 1)リンパ節転移の有無で有意差あり(P<0.01), 2)遠隔転移の有無でも有意差あり(P<0.01), 3)静脈浸潤の有無では有意差がなかった.4)各細胞型群間には有意差なく, 5)術前の腎動脈塞栓術の有無にも有意差はなかった.各治療群(MMC, VBL, BRM)間に有意差はなかったが, VBLで生存率がやや良好であった

A retrospective study was carried out on 95 patients affected with renal cell carcinoma (RCC) between January 1973 and December 1988. Male to female ratio was 3 to 1 and the average age was 61 years. Hematuria was the most common initial symptom (44 patients, 46.3%), followed by incidental findings (18 patients, 18.9%). Five- and 10-year survival rates for all patients with RCC were 51.9 and 37.1%, respectively. Five-year survival rates for stage I, II, III, and IV were 82.7 54.7, 20.0, and 4.7%, respectively. Statistical analyses identified variables that significantly influenced survival, including lymph node metastasis (p less than 0.01) and distant metastasis (p less than 0.01). Cell type and renal vein involvement did not influence survival significantly. The three different forms of therapy (mitomycin therapy vincristine therapy and immunological therapy) did not influence survival significantly, but the beneficial effect of VBL therapy was obtained.